In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: An overview

Inflammation Research

Volumn 46, Issue 11, 1997, Pages 437-446

  Famaey, J P ^a  

^a Therabel Pharma Belgium   (Belgium)

Author keywords

Cyclooxygenase 2; Nimesulide

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; THROMBOXANE B2;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SELECTIVITY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; META ANALYSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; PROSTAGLANDIN SYNTHESIS INHIBITION; REVIEW; STOMACH MUCOSA;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFLAMMATION; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONAMIDES; THROMBOXANE B2;

EID: 0030682072     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050221     Document Type: Review

References (114)

1. 2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990;265: 16737-40.
2. Masferrer JL, Zweifel BS, Seibert K, Needleman P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 1990;86:1375-9.
3. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase-cyclooxygenase homologue. J Biol Chem 1991;266: 12866-72.
4. O'Banion MK, Sadowski HB, Winn VD, Young DA. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991;266:23261-7.
5. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692-
6. Hla T, Neilson K, Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992;89:7384-8.
7. Seibert K, Masferrer JL. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor 1994;4:17-23.
8. Sirois J, Richards JS. Purification and characterization of a novel, distinct isoform of prostaglandin endoperoxide synthase induced by human chorionic gonadotrophin in granulosa cells of rat preovulatory follicles. J Biol Chem 1992;267:6383-8.
9. Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald GA. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression and gene chromosomal assignment. FASEB J 1991;5:2304-12.
10. Goppelt-Struebe M. Regulation of prostaglandin endoperoxide synthase (cyclooxygenase) isozyme expression. Prostaglandins, Leukotrienes and Essential Fatty Acids 1995;52:213-22.
11. Smith WL, Meade EA, De Witt DL. Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann NY Acad Sci 1994;744:50-7.
12. Isakson PC. Synthesis and pharmacology of selective COX-2 inhibitors. Med Chem Res 1995;5:344-50.
13. De Witt DL, Meade EA, Smith WL. PGH synthase isoenzyme selectivity: The potential for safer nonsteroidal anti-inflammatory drugs. Am J Med 1993;95 (Suppl 2A):40S-4S.
14. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994;91:12013-7.
15. De Witt DL. Prostaglandin endoperoxide synthase: Regulation of enzyme expression. Biochim Biophys Acta 1991;1083:121-34.
16. Oshima T, Yoshimoto T, Yamamoto S, Kumegawa S, Yokoyama C, Tanabe T. cAMP-dependent induction of fatty acid cyclooxygenase mRNA in mouse osteoblastic cells (MC3T3-E1). J Biol Chem 1991;266:13621-6.
17. Crofford LJ, Wilder RL, Ristimäki AP, Sano H, Remmers EF, Epps HR, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1β, phorbol ester and corticosteroids. J Clin Invest 1994;93:1095-101.
18. O'Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA 1992;89:4888-92.
19. Lee SH, Soyoola E, Chanmugam P, Harts S, Sun W, Zhong H, et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharides. J Biol Chem 1992;267:25934-8.
20. O'Sullivan MG, Huggins Jr EM, Meade EA, De Witt DL, McCall CE. Lipopolysaccharide induces prostaglandin H synthase-2 in alveolar macrophages. Biochem Biophys Res Commun 1992;187:1123-7.
21. Sano H, Hla T, Maier JAM, Crofford LJ, Case JP, Maciag T et al. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest 1992; 89:97-108.
22. Masferrer JL, Seibert K, Zweifel B, Needleman P. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci USA 1992;89:3917-21.
23. Masferrer JL, Reddy ST, Zweifel BS, Seibert K, Needleman P, Gilbert RS, et al. In vivo glucocorticoids regulate cyclooxygenase-2 but not cylooxygenase-1 in peritoncal macrophages. J Pharmacol Exp Ther 1994;270:1340-4.
24. Battistini B, Botting R, Bakhle YS, COX-1 and COX-2: Toward the development of more selective NSAIDs. Drug News Perspect 1994;7:501-12.
25. Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, Ponta H, el al. Antitumor promotion and anti-inflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 1990;62:1189-204.
26. Engelhardt G. Meloxicam. A potent inhibitor of COX-2. In: Abstract book of the 9th International Congress on Prostaglandins and Related Compounds: 1994 June 6-10, Florence (Italy), 1994:P82.
27. Engelhardt G, Bögel R, Schnitzer C, Utzmann R. Meloxicam: Influence on arachidonic acid metabolism. Part 1. In vitro findings. Biochem Pharmacol 1996;51:21-8.
28. Mitchell JA, Akarasereeont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1994;90:11693-7.
29. Akarasereeont P, Mitchell JA, Thiemermann C, Vane JR. Relative potency of nonsteroid anti-inflammatory drugs as inhibitors of cyclooxygenase-1 or cyclooxygenase-2 [abstract]. Br J Pharmacol 1994;110:183P.
30. Laneuville O, Breuer DK, De Witt DL, Hla T, Funk CD, Smith WL. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994;271:927-34.
31. Meade EA, Smith WL, De Witt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610-4.
32. Vane JR. Towards a better aspirin. Nature 1994;367:215-6.
33. Vane JR, Botting RM. Mechanisms of action of anti-inflammatory drugs. In: Bochringer Ingelheim GmBH, editor. Proceedings of the symposium Selective Cyclo-Oxygenase Inhibition. Promise for future NSAID therapy; 1995 June 19. Amsterdam (The Netherlands), Adelphi Communications Ltd, 1995;13-8.
34. Gierse JK, Hauser SD, Creely DP, Koboldt C, Rangwala SH, Isakson PC, et al. Expression and selective inhibition of the constitutive and inducible forms of human cyclooxygenase. Biochem J 1995;305:479-84.
35. Barnett J, Chow J, Ives D, Chiou M, Mackenzie R, Osen E, et al. Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim Biophys Acta 1994;1209:130-9.
36. Churchill L, Graham A, Farina P, Grob P. Inhibition of human cyclooxygenase-2 (COX-2) by meloxicam. In: Selective cyclooxygenase inhibition. Promise for future NSAID therapy? Proceedings of a symposium held in Amsterdam, 19 June 1995. Bochringer Ingelheim, Adelphi Communications Ltd, 1995:32-3.
37. Tofanetti O, Casciarri I, Cipolla PV, Cazzulani P, Omini C. Effect of nimesulide on cyclooxygenase activity in rat gastric mucosa and inflammatory exudate. Med Sci Res 1989;17:745-6.
38. Ceserani R, Casciarri I, Cavaletti E, Cazzulani P. Action of nimesulide on rat gastric prostaglandins and renal function. Drug Invest 1991;3 (Suppl 2):14-21.
39. Tanaka K, Shimotori S, Makino S, Aikawa Y, Inata T, Yoshida C, et al. Pharmacological studies of the new anti-inflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one. First communication: Anti-inflammatory, analgesic and other related properties. Arzneim Forsch/Drug Res 1992;42:935-44.
40. Rainsford KD. The comparative gastric ulcerogenic activities of non-steroid anti-inflammatory drugs. Agents Actions 1977;7: 573-7.
41. Carr DP, Henn R, Green JR. Comparison of the systemic inhibition of thromboxane synthesis, anti-inflammatory activity and gastrointestinal toxicity of non-steroidal anti-inflammatory drugs in the rat. Agents Actions 1986;19:374-5.
42. Godessart N, Salcedo C, Fernandez AG, Patacios JM. Anti-inflammatory and gastrointestinal lesive effects of novel and classical NSAIDs in rats after acute and subacute treatments. In: Abstract book of the 10th International Conference on Prostaglandins and related Compounds; 1996 Sept 22-27; Vienna (Austria), 1996:P94.
43. Tavares IA, Bennett A. Activity of nimesulide on constitutive and inducible prostaglandin cyclo-oxygenase. In: Abstract book of the 6th Interscience World Conference on Inflammation, Antirheumatics, Analgesics, Immunomodulators 95; 1995 March 28-30, Geneva (Switzerland), 1995:108.
44. Tavares IA, Bishai PM, Bennett A. Activity of nimesulide on constitutive and inducible cyclooxygenases. Arzneim Forsch/Drug Res 1995;45:1093-5.
45. Davis R, Brogden RN, Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1994;45:431-54.
46. Vago T, Bevilacqua M, Norbiato G. Effect of nimesulide action time dependence on selectivity towards prostaglandin G/H synthase/cyclooxygenase activity. Arzneim Forsch/Drug Res 1995;45:1096-8.
47. Taniguchi Y, Ikesue A, Yokoyania K, Noda K, Debuchi H, Nakamura T, et al. Selective inhibition by nimesulide, a novel non-steroidal anti-inflammatory drug with prostaglandin endoperoxide synthase-2 activity in vitro. Pharm Sci 1995;1:173 5.
48. Bennett A, Tavares IA. NSAIDs. COX-2 inhibitors and the gut. Lancet 1995;346:1105.
49. Wallace JL, Granger DN. The pathogenesis of NSAID-gastropathy. Are neutrophils the culprits? Trends Pharmacol Sci 1992; 13:129-31.
50. Wallace JL. The 1994 Merck Frosst Award. Mechanisms of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal damage - potential for development of gastrointestinal tract safe NSAIDs. Can J Physiol Pharmacol 1994;72:1493-8.
51. Tavares IA, Bishai PM, Bennett A. Nimesulide selectively inhibits COX-2. In: William Harvey Research Conferences (1996). Vol. 8. Abstract book of the symposium New Target in inflammation: Inhibitors of COX-2 or adhesion molecules; 1996 April 15-16, New Orleans (Lo), 1996:42, P25.
52. Tavares IA, Bishai PM, Bennett A. Nimesulide selectively inhibits COX-2. In: William Harvey Research Conferences (1996). Vol. 8. Abstract book of the symposium New Target in inflammation: Inhibitors of COX-2 or adhesion molecules; 1996 April 15-16, New Orleans (Lo), 1996:42, P25.
53. Copeland RA, Williams JM, Rider NL, Vandyk DE, Giannaras J, Nurnberg S, et al. Selective time-dependent inhibition of cyclooxygenase-2. Med Chem Res 1995;5:384-93.
54. Carabaza A, Cabre F, Rotllan E, Calvo M, Gutierrez M, Gomez M, et al. Effect of COX-2 inhibitors on constitutive and inducible cyclooxygenase activity from different sources. Comparison with antiinflammatory activity. In: Abstract book of the 10th International Conference on Prostaglandins and Related Compounds: 1996 Sept 22-27, Vienna (Austria), 1996:P93.
55. Vojnovic J, Amirmansour C, Warner TD, Vane JR. Nimesulide: selectivity for COX-2 over COX-1. In: William Harvey Research Conferences (1995) Vol. 7. Abstract book of the symposium Improved non-steroid anti-inflammatory drugs; COX-2 enzyme inhibitors; 1995 Oct 10-11, London (UK), 1995:22, P4.
56. Vojnovic J, Amirmansour C, Warner TD, Vane JR. Nimesulide: selectivity for COX-2 over COX-1. In: William Harvey Research Conferences (1995) Vol. 7. Abstract book of the symposium Improved non-steroid anti-inflammatory drugs; COX-2 enzyme inhibitors; 1995 Oct 10-11, London (UK), 1995:22, P4.
57. Chan CC, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, et al. Pharmacology of a selective cyclooxygenase inhibitor, L745,337: A novel non-steroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 1995;274:1531-7.
58. Prasit P, Black WC, Chan CC, Ford-Hutchinson AW, Gauthier JY, Gordon R, et al. L-745,337: A selective cyclooxygenase-2 inhibitor. Med Chem Res 1995;5:364 74.
59. Churchill L, Graham AG, Shih CK, Pauletti D, Farina PR, Grob PM. Selective inhibition of human cyclooxygenase-2 by meloxicam. Inflammopharmacology 1996;4:125-35.
60. Grossman CJ, Wiseman J, Lucas FS, Trevethick MA, Birch PJ. Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and COX-2 inhibitors, Inflamm Res 1995;44:253-7.
61. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994;271:1705-12.
62. Glaser K, Sung ML, O'Neill K, Belfast M, Hartman D, Carlson R, et al. Etodolac selectivity inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol 1995;281:107-11.
63. Panara MR, Greco A, Santini G, Sciulli MG, Rotondo MT, Padovano R, et al. Effect of the novel anti-inflammatory compounds N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulphonamide (NS-398) and 5-methanesulphonamido-6-(2,4-difluorothiophenyl)-1-indanone (L- 745337), on the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. Br J Pharmacol 1995; 116:2429-34.
64. Brideau C, Kargman S, Liu S, Dalloh AL, Enrich EW, Rodger IW, et al. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 1996;45:68-74.
65. Patrono C, Patrignani P, Panara MR, Cippollone F, Santini G, Sciulli MG, et al. COX-2 expression and inhibition in human monocytes. In: Vane JR, Botting J, Botting R, editors. Improved non-steroid anti-inflammatory drugs. COX-2 enzyme inhibitors. Dordrecht: Kluwer, 1996;121-31.
66. Patrignani P, Panara MR, Santini G, Sciulli MG, Padovano R, Cippollone F, et al. Differential inhibition of the cyclooxygenase activity of prostaglandin endoperoxide synthase isozymes in vitro and ex vivo. In: Abstract book of the 10th International Conference on Prostaglandins and Related Compounds; 1996 Sept 22-27, Vienna (Austria), 1996:P115.
67. Cullen L, Kelly L, Forde R, Fitzgerald D. Selective suppression of COX-2 during chronic administration of nimesulide in man. In: William Harvey Research Conferences (1997). Vol. 11. Abstract book of the symposium Selective COX-2 Inhibitors: Pharmacology, clinical effects and therapeutic potential; 1997 March 20-21, Cannes (France), 1996:27, P3.
68. Cullen L, Kelly L, Forde R, Fitzgerald D. Selective suppression of COX-2 during chronic administration of nimesulide in man. In: William Harvey Research Conferences (1997). Vol. 11. Abstract book of the symposium Selective COX-2 Inhibitors: Pharmacology, clinical effects and therapeutic potential; 1997 March 20-21, Cannes (France), 1996:27, P3.
69. Huff R, Collins P, Kramer S, Seibert K, Koboldt C, Gregory S, et al. A structural feature of N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulfonamide (NS-398) that governs its selectivity and affinity for cyclooxygenase 2 (COX-2). Inflamm Res 1995;44 Suppl 2:S145-6.
70. Futaki N, Arai I, Hamasaka Y, Takahashi S, Higuchi S, Otomo S. Selective inhibition of NS-398 on prostanoid production in inflamed tissue in rat carrageenin air pouch inflammation. J Pharm Pharmacol 1993;45:753-5.
71. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994;47:55-9.
72. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, et al. Selective inhibition of inducible cyclooxygenase-2 in vivo is anti-inflammatory and non-ulcerogenic. Proc Natl Acad Sci USA 1994;91:3228-32.
73. Ouellet M, Percival MD. Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J 1995; 306:247-51.
74. Hirschelmann R, Hentschel M, Geissler J, Rickinger O. CGP 28,238, a new potent nonsteroidal anti-inflammatory agent: Its relation to arachidonic acid metabolism. Agents Actions 1991; 32:54-5.
75. Klein T, Nüsing RM, Pfeilschifter J, Ullrich V. Selective inhibition of cyclooxygenase 2. Biochem Pharmacol 1994;48:1605-10.
76. Aslanian R, Carruthers NI, Kaminski JJ. Cyclooxygenase-2: A novel target for therapeutic intervention. Exp Opin Invest Drugs 1994;3:1323-5.
77. Boyce S, Chan CC, Gordon R, Li CS, Rodger IW, Webb JK, et al. L-745,337: A selective inhibitor of cyclooxygenase-2 elicits antinociception but not gastric ulceration in rats. Neuropharmacol 1994;33:1609-11.
78. Tanaka K, Kawasaki H, Kurata K, Aikawa Y, Tsukamoto Y, Inaha T. T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts. Jpn J Pharmacol 1995;67:305-14.
79. Purnham MJ. Inhibitors of inducible cyclooxygenase (COX-2): Anti-inflammatory drugs with improved tolerability? Exp Opin Invest Drugs 1996;5:111-4.
80. Ford-Hutchinson A. New highly selective COX-2 inhibitors. In: William Harvey Research Conferences (1997). Vol 11, Abstract book of the symposium Selective COX-2 Inhibitors: Pharmacology, clinical effects and therapeutic potential: 1997 March 20-21, Cannes (France), 1997:23.
81. Tanaka K, Iizuka Y, Yoshida N, Tomita K, Masuda H. Diaryl Pyrroles: A new series of anti-inflammatory agents. Experientia 1972;28:937-8.
82. Gans KR, Galbraith W, Roman RJ, Haber SB, Kerr JS, Schmidt WK, et al. Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther 1990;254:180-7.
83. Jensen NP. NSAIDs revisited. Cyclooxygenase-2 (COX-2) inhibitors. Med Chem. Res 1995;5:319-24.
84. Reitz DB, Li JL, Norton MB, Reinhard EJ, Huang HC, Penick MA, et al. Novel 1,2-diarylcyclopentenes are selective, potent and orally active cyclooxygenase inhibitors. Med Chem Res 1995;5:351-63.
85. Needleman P. Development of novel COX-2 inhibitors. In: William Harvey Research Conferences (1997). Vol. 11, Abstract book of the symposium Selective COX-2 Inhibitors: Pharmacology, clinical developments and therapeutic potential; 1997 March 20-21, Cannes (France), 1997:24.
86. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (New Biol) 1971;231: 232-5.
87. Vane JR, Flower RJ, Botting RM. The mechanism of action of aspirin. In: Vane JR, Botting RM, editors. Aspirin and other salicylates. London: Chapman & Hall, 1992:35-59.
88. De Witt DL, Bhattacharyya D, Lecomte M, Smith WL. The differential susceptibility of prostaglandin endoperoxide H synthases-1 and -2 to nonsteroidal anti-inflammatory drugs: Aspirin derivatives as selective inhibitors. Med Chem Res 1995; 5:325-43.
89. Carty TJ, Stevens JS, Lombardino JG, Parry MJ, Randall MJ. Piroxicam, a structurally novel anti-inflammatory compound. Mode of prostaglandin synthesis inhibition. Prostaglandins 1980; 19:671-82.
90. Rome LH, Lands WEM. Structural requirement for time-dependent inhibition of prostaglandins biosynthesis by anti-inflammatory drugs. Proc Natl Acad Sci USA 1975;72:4863-5.
91. Kulmacz RJ, Lands WEM. Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents. J Biol Chem 1985;260:12572-8.
92. Walenga RW, Wall SF, Setty BN, Stuart MJ. Time-dependent inhibition of platelet cyclooxygenase by indomethacin is slowly reversible. Prostaglandins 1986;31:625-37.
93. Shimokawa T, Smith WL. Prostaglandin endoperoxide synthase. The aspirin acetylation region. J Biol Chem 1992;267: 12387-92.
94. De Witt DL, El-Harith EA, Kraemer SA, Andrews MJ, Yao EF, Armstrong RL, et al. The aspirin and hemi-binding site of ovine and murine prostaglandin endoperoxide synthase. J Biol Chem 1990;265:5192-8.
95. Lecomte M, Laneuville O, Ji C, De Witt DL, Smith WL. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem 1994;269:13207-15.
96. Copeland RA, Williams JM, Giannaras J, Nurnberg S, Covington M, Pinto D, et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci USA 1994;91:11202-6.
97. Futaki F, Yoshikawa K, Hamasaka Y, Arai I, Higuchi S, Izuka H, et al. NS-398, a novel nonsteroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 1993;24:105-10.
98. Bourgeois P, Dreiser RL, Lequesne MG, Macciochi A, Monti T. Multi-centre double-blind study to define the most favourable dose of nimesulide in terms of efficacy/safety ratio in the treatment of osteoarthritis. Eur J Rheum Infl 1994;14:39-50.
99. Gamarski J. Treatment of degenerative arthropathies with nimesulide [Portuguese]. Rev Bras Med 1981;38:309-12.
100. Dreiser RL, Riebenfeld D. Nimesulide in the treatment of osteoarthritis. Double-blind studies in comparison with piroxicam, ketoprofen and placebo. Drugs 1993;46 (Suppl 1):191-5.
101. Blardi P, Gatti F, Auteri A, Di Perri T. Effectiveness and tolerability of nimesulide in the treatment of osteoarthritic elderly patients. Int J Tiss Reac 1992;14:263-8.
102. Quattrini M, Paladin S. A double-blind study comparing nimesulide with naproxen in the treatment of osteoarthritis of the hip. Clin Drug Invest 1995;10:139-46.
103. Porto A, Almeida H, Cunha MJ, Macciochi A. Double-blind study evaluating by endoscopy the tolerability of nimesulide and diclofenac on the gastric mucosa in osteoarthritic patients. Eur J Rheum Infl 1994;14:33-8.
104. Lücker PW, Pawlowski C, Friederich I, Faiella F, Magni E. Double-blind, randomised, multi-centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodolac in patients suffering from osteoarthritis of the knee. Eur J Rheum Infl 1994;14:29-38.
105. Lecomte J, Buyse H, Taymans J, Monti T. Treatment of tendinitis and bursitis: A comparison of nimesulide and naproxen sodium in a double-blind parallel trial. Eur J Rheum Infl 1994;14: 29-39.
106. Rabasseda X. Safety profile of nimesulide: Ten years of clinical experience. Drugs of Today 1997;33:41-50.
107. Biscarini L. Anti-inflammatory analgesics and drugs used in gout. In: Dukes MNG, et al. Meyler's side-effects of drugs, 12th ed. Amsterdam: Elsevier, 1992:181-234.
108. Cox NL, Doherty SM. Non-steroidal anti-inflammatories: Outpatient audit of patients preferences and side-effects in different diseases. In: Rainsford KD, Velo GP, editors. Side-effects of anti-inflammatory drugs. Part 1. Clinical and epidemiological aspects. Lancaster: MTP Press, 1985:137-150.
109. Day RO, Graham GG, Williams Km, Champion GD, de Jager J. Clinical pharmacology of non-steroidal anti-inflammatory drugs. In: Orme M, editor. Antirheumatic drugs. New York: Pergamon Press, 1990:137-87.
110. Pochobradsky MG, Mele G, Beretta A, Montagnani G. Post-marketing survey of nimesulide in the short-term treatment of osteoarthritis. Drugs Exp Clin Res 1991;17:197-204.
111. Memeo A, Montagnani G. Nimesulide in the treatment of post-traumatic pathologies. A multicenter study [Italian]. Minerva Ortop Traumatol 1991;42:343-5.
112. Mele G, Memeo A, Mellesi L, Gatti F. Post-marketing surveillance of nimesulide in the treatment of 8,354 patients over 60 years old affected with acute and chronic musculoskeletal diseases [Italian]. Arch Med Interna 1992;44:213-21.
113. Marini U, Spotti D, Magni E, Monti T. Double-blind endoscopic study comparing the effect of nimesulide and placebo on gastric mucosa of dyspeptic patients. Drug Invest 1990;2:162-6.
114. Cipollini F, Mecozzi V, Altilia F. Endoscopic assessment of the effects of nimesulide on the gastric mucosa: Comparison with indomethacin. Curr Ther Res 1989;45:1042-8.